Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-07-31

FDA Approved: ALYACEN 1/35 — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

FDA approved a supplemental application for ALYACEN 1/35, a generic combined oral contraceptive containing norethindrone and ethinyl estradiol, manufactured by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALYACEN 1/35 (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for ALYACEN 1/35 (NORETHINDRONE AND ETHINYL ESTRADIOL)